Annexon (NASDAQ:ANNX) Shares Up 6.6% - What's Next?
Annexon (NASDAQ:ANNX) stock surged by 6.6% on Monday, trading at $5.8650, despite lower-than-average trading volume. Analysts hold a "Moderate Buy" consensus with an average price target of $17.00, driven by the company's lead asset, ANX005, which is in Phase 2 trials for neurological conditions. While institutions have significantly increased their holdings, company insiders have recently sold shares.
HC Wainwright Estimates Annexon FY2030 Earnings
HC Wainwright has projected Annexon's (NASDAQ:ANNX) FY2030 earnings per share (EPS) to be $0.43, a significant increase from the Street's consensus of ($0.96) per share. This revision follows Annexon's recent quarterly EPS of ($0.28), which beat analyst estimates by $0.04. The clinical-stage biotech company is currently trading around $5.50, with an average analyst target price of $17, indicating a "Moderate Buy" consensus.
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright has reiterated its Buy rating for Annexon (ANNX.US) and maintained its target price at $14. This indicates a continued positive outlook from the analytical firm regarding Annexon's stock performance and potential.
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Annexon (NASDAQ:ANNX) has seen its share price soar by 183% in the last year, despite being an unprofitable company. The company had a cash runway of about 15 months as of December 2025, with analysts forecasting it to break even in approximately 4 years. While the increased cash burn of 58% over the last year is concerning, the company's solid cash runway and analyst forecasts for profitability suggest a manageable, though closely monitored, financial situation.
Multiple Insiders Sold Annexon Shares Presenting Weak Signs For Investors
The article highlights recent insider selling of Annexon (NASDAQ: ANSS) shares, which could be interpreted as a negative signal for investors. While some insider selling is routine, widespread selling across multiple insiders might suggest a lack of confidence in the company's future prospects. Investors should consider these transactions as part of their due diligence when evaluating the stock.
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline with anticipated milestones for 2026. The company is advancing vonaprument for Geographic Atrophy (GA) with pivotal Phase 3 data expected in Q4 2026, tanruprubart for Guillain-Barré Syndrome (GBS) with a European MAA filed and U.S. BLA planned for 2026, and ANX1502 for autoimmune diseases. Annexon also reported a strong balance sheet with $238.3 million in cash and equivalents as of December 31, 2025, providing a cash runway into the second half of 2027.
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon (NASDAQ: ANNX) reported its Q4 and full-year 2025 financial results, highlighting significant progress in its clinical pipeline. Key anticipated milestones include topline Phase 3 data for vonaprument in Geographic Atrophy in Q4 2026, a European MAA filing for tanruprubart in Guillain-Barré Syndrome with a planned U.S. BLA submission in 2026, and proof-of-concept data for ANX1502 in autoimmune disease in 2026. The company maintains a strong balance sheet with $238.3 million in cash as of December 31, 2025, providing an anticipated runway into the second half of 2027.
Annexon (NASDAQ:ANNX) Shares Gap Up - Should You Buy?
Annexon (NASDAQ:ANNX) shares gapped up by approximately 6.6% on Tuesday, opening at $5.64 after closing at $4.96. The clinical-stage biotech company, which focuses on complement-targeted therapies for neurodegenerative and neuroimmune diseases, holds a "Moderate Buy" consensus rating from analysts with an average price target of $17.00. Recent insider transactions show executives selling shares, while institutional investors have adjusted their positions, with the company reporting quarterly earnings per share of ($0.32), meeting analyst estimates.
Needham Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $11
Needham has reiterated its Buy rating for Annexon (ANNX.US) and maintained a target price of $11. This decision reflects the firm's continued positive outlook on the company's stock.
Annexon (NASDAQ:ANNX) Releases Earnings Results, Hits Expectations
Annexon (NASDAQ:ANNX) announced earnings per share of ($0.32), meeting analyst expectations. The stock saw a slight dip to $4.96. Insider transactions were mixed with a director purchasing shares and an EVP selling, while hedge funds increased their holdings.
Annexon Reports Positive Q4 and Full-Year 2025 Results, Highlights Key Milestones
Annexon, a biopharmaceutical company, announced positive Q4 and full-year 2025 financial results, highlighting significant progress in its immunotherapy programs for neuroinflammatory diseases. Key milestones include upcoming Phase 3 data for vonaprument in geographic atrophy, European MAA filing for tanruprubart in Guillain-Barré syndrome, and advancement of ANX1502 in autoimmune disease trials, aiming to address large underserved markets. The company's approach targets the classical complement pathway to provide meaningful functional benefits for patients.
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating
This article reports that TD Cowen has reiterated its Buy rating on Annexon (ANNX.US). No additional details are provided in the content.
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline for neuroinflammatory diseases. Key milestones include expected topline pivotal data for vonaprument in Geographic Atrophy (GA) in Q4 2026, an MAA filing in Europe for tanruprubart for Guillain-Barré Syndrome (GBS), and anticipated proof-of-concept data for ANX1502 for autoimmune conditions in 2026. The company also reported a strong balance sheet with $238.3 million in cash and equivalents, providing an anticipated runway into the second half of 2027.
Annexon (NASDAQ: ANNX) widens 2025 loss but extends cash runway into 2027
Annexon (NASDAQ: ANNX) reported a widened net loss of $208.5 million in 2025 due to increased R&D spending on its late-stage neuroinflammatory pipeline. Despite the loss, the company extended its cash runway into the second half of 2027, with $238.3 million in cash and investments. Annexon is progressing three key programs: vonaprument for geographic atrophy with topline Phase 3 data expected in Q4 2026, tanruprubart for Guillain-Barré syndrome with an MAA filed in Europe and BLA submission planned for 2026, and oral C1 inhibitor ANX1502 for autoimmune disease with POC data anticipated in 2026.
Annexon, Inc. (NASDAQ:ANNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Annexon, Inc. (NASDAQ:ANNX) has received a consensus "Moderate Buy" rating from seven analysts, with an average one-year price target of $17.00. While insiders recently sold shares, several institutional investors, including Adage Capital Partners and State Street Corp, significantly increased their stakes in the company during the fourth quarter. Annexon is a clinical-stage biotechnology company focused on developing complement-targeted therapies for neurodegenerative and neuroimmune diseases.
Vanguard disaggregates holdings; Annexon (ANNX) shows 0 shares reported
Vanguard has filed an amended Schedule 13G/A for Annexon Inc (ANNX), reporting 0 shares beneficially owned and 0% of common stock. This change follows an internal realignment effective January 12, 2026, where Vanguard's subsidiaries will now report ownership separately, in reliance on SEC Release No. 34-39538. While Vanguard itself reports no beneficial ownership, it retains the right to receive dividends or proceeds, and specific institutional ownership will be disclosed in future separate filings by its subsidiaries.
Are Healthcare Stocks Falling Behind American Well (AMWL) in Performance This Year?
American Well Corporation (AMWL) has significantly outperformed its Medical sector peers and its specific industry in 2024, showing a 16.7% return while the sector declined by 6.7% and its industry by 22.7%. The company holds a Zacks Rank #2 (Buy), with analysts raising earnings estimates by 36.6% in the last quarter. Annexon, Inc. (ANNX) is another Medical stock showing strong performance, with a 1.8% gain year-to-date.
Are Healthcare Stocks Falling Behind American Well (AMWL) in Performance This Year?
American Well Corporation (AMWL) has significantly outperformed its Medical sector peers and industry year-to-date, with a 16.7% return compared to the sector's 6.7% decline. The company holds a Zacks Rank #2 (Buy), reflecting increased analyst optimism and rising earnings estimates. Annexon, Inc. (ANNX) is another Medical stock showing strong performance, also with a Zacks Rank #2 (Buy).
If You Invested $1,000 in Annexon, Inc. (ANNX)
This article examines the historical performance of a $1,000 investment in Annexon, Inc. (ANNX) over various periods, showing significant returns in the short term but substantial losses over longer periods compared to the S&P 500. It also provides an in-depth company profile, detailing Annexon's focus on developing therapies for neuroinflammatory and complement-mediated diseases, its key product candidates, and its clinical development pipeline.
Analysts Offer Insights on Healthcare Companies: Annexon Biosciences (ANNX) and Electrocore (ECOR)
This article highlights bullish analyst ratings for two healthcare companies: Annexon Biosciences (ANNX) and Electrocore (ECOR). H.C. Wainwright analysts maintained Buy ratings for both, with price targets of $14.00 for Annexon Biosciences and $18.00 for Electrocore, reflecting significant upside potential for investors.
ANNX PE Ratio & Valuation, Is ANNX Overvalued
Annexon Inc (ANNX) is currently in the "Fair zone" according to its forward PS ratio, which is 0.00 compared to a five-year average of -3.40. Its fair price is estimated to be between NaN to NaN based on relative valuation. However, ANNX's current P/B ratio of 3.34 is significantly higher than its 3-year and 5-year averages, and its P/S ratio of 0.00 is -100% above the industry average, which is deemed unsustainable given its robust revenue growth.
Annexon, Inc. (ANNX) Discusses Vision Preservation in Geographic Atrophy With C1q Inhibition and Key Insights From ARCHER Trials - Slideshow (NASDAQ:ANNX) 2026-03-20
Annexon, Inc. (ANNX) presented a slideshow discussing vision preservation in geographic atrophy through C1q inhibition, sharing key insights from their ARCHER trials. The company's transcripts team published this content, focusing on developments related to their research.
Chardan Capital Maintains Buy Rating on Annexon (ANNX) with $16 Price Target | ANNX Stock News
Chardan Capital has reaffirmed its Buy rating for Annexon (ANNX) and maintained a $16 price target, showing continued confidence in the stock. This follows other recent "Buy" and "Overweight" ratings from firms like Clear Street, Wells Fargo, and HC Wainwright & Co. Annexon is a clinical-stage biopharmaceutical company developing therapies for classical complement-mediated disorders, with Wall Street analysts forecasting an average target price of $14.71, implying a significant upside from its current price.
Annexon's (ANNX) "Buy" Rating Reaffirmed at Chardan Capital
Chardan Capital has reaffirmed a "Buy" rating for Annexon (ANNX) with a $16 price target, suggesting a potential upside of 191% from its recent closing price. The company, a clinical-stage biotech focusing on complement-targeted therapies, currently holds a "Moderate Buy" consensus rating among analysts with an average target of $17. Large institutional investors have increased their holdings, and insider selling has also been noted.
Chardan Capital Maintains Buy Rating on Annexon (ANNX) with $16 Price Target
Chardan Capital has reiterated its Buy rating for Annexon (ANNX) and maintained a price target of $16.00, reflecting continued confidence in the stock. This decision follows previous ratings from various firms, with the average analyst target price for ANNX currently at $14.71, implying significant upside from its current trading price. Annexon is a clinical-stage biopharmaceutical company focused on developing therapies for complement-mediated disorders.
ANNX Earnings History & Surprises | EPS & Revenue Results | ANNEXON INC (NASDAQ:ANNX)
This article provides a detailed historical overview of ANNEXON INC (ANNX) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It highlights past performance, showing that ANNX has beaten EPS estimates in 1 out of the last 4 quarters, with an average EPS miss of 10.1% over that period. The report also lists the next anticipated earnings release date, May 11, 2026, for Q4 2025.
Annexon Investor Day: ANX007 Targets C1q in Dry AMD GA as Phase III Readout Nears Q4
Annexon presented at its Investor Day, highlighting the scientific rationale and clinical progress of ANX007 (vonoprument) for geographic atrophy (GA) secondary to dry age-related macular degeneration. The company emphasizes that ANX007 targets the upstream complement initiator C1q to preserve photoreceptors and visual function, a strategy they believe differentiates it from downstream inhibitors. With topline results for the ARCHER II Phase III study expected in Q4 this year, Annexon aims to address a significant unmet need in retinal care by focusing on vision preservation rather than solely slowing lesion growth.
ANNX: Phase III trial for C1q inhibition in GA is fully enrolled, with results expected in Q4
Annexon, Inc. (ANNX) has fully enrolled its Phase III ARCHER II trial for C1q inhibition in Geographic Atrophy (GA), with results anticipated in Q4. This novel approach aims to preserve vision by protecting photoreceptors, supported by strong functional and structural benefits observed in Phase II data. The trial is highly powered and aligned with regulators.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced an inducement grant to a new non-executive employee under Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 20,000 shares of Annexon common stock at an exercise price of $5.66, vesting over four years. This grant aligns with the company's 2022 Employment Inducement Award Plan to attract and retain talent.
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced an inducement grant to a new non-executive employee under Nasdaq Listing Rule 5635(c)(4). The employee received an option to purchase 20,000 shares of Annexon common stock, with an exercise price of $5.66, vesting over four years. This grant aligns with the company's biopharmaceutical focus on neuroinflammatory diseases.
Biopharmaceutical Annexon offers new hire 20,000-share option grant
Annexon (Nasdaq: ANNX) has granted a new non-executive employee an inducement option to purchase 20,000 shares of its common stock. The award was approved on March 12, 2026, with an exercise price of $5.66 per share, matching the closing price on the grant date of March 13, 2026. This option has a ten-year term and vests over four years, with an initial 25% vesting after one year, followed by monthly vesting for the remainder.
ANNX SEC Filings - Annexon, Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Annexon, Inc.'s (ANNX) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features recent filings with AI-powered summaries, such as BlackRock's disclosed stake, corporate deck updates for J.P. Morgan,
William Carson Acquires 8,000 Shares of Annexon (NASDAQ:ANNX) Stock
William Carson, a Director at Annexon (NASDAQ:ANNX), recently purchased 8,000 shares of the company's stock for $5.67 per share, totaling $45,360, increasing his stake by 14.7%. This acquisition boosts his total holdings to 62,405 shares. The purchase comes as analyst sentiment for Annexon shifts positively, with firms like Wells Fargo raising price targets and a consensus "Moderate Buy" rating for the clinical-stage biotechnology company.
[Form 4] Annexon, Inc. Insider Trading Activity
Annexon, Inc. director William H. Carson reported an open-market purchase of 8,000 shares of Common Stock at $5.67 per share. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. Following this purchase, Carson directly owns 62,405 shares of Annexon.
Annexon (NASDAQ:ANNX) Stock Price Down 8.1% - Should You Sell?
Annexon (NASDAQ:ANNX) experienced an 8.1% drop in its stock price during mid-day trading on Thursday, with significantly lower trading volume than its daily average. Despite this decline and recent insider selling, analyst sentiment remains a "Moderate Buy" with an average price target of $17. Institutional investors have also substantially increased their holdings in the company.
Insider Buying: William Carson Acquires 8,000 Shares of Annexon Inc (ANNX)
Director William Carson of Annexon Inc (ANNX) recently purchased 8,000 shares, increasing his total holdings to 62,405 shares. This transaction on March 10, 2026, where shares were priced at $5.67, reflects a broader trend of insider activity for the biopharmaceutical company, which recorded 11 insider buys against 13 sells over the past year. Such insider purchases are often interpreted as a sign of confidence in the company's future prospects.
ANNX SEC Filings - Annexon, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Annexon, Inc. (ANNX) SEC filings, including annual reports (10-K), quarterly reports (10-Q), material event reports (8-K), and insider trading forms (Form 4). It highlights recent filings such as executive stock sales for tax withholding, the planned retirement of the Chairman of the Board, and significant ownership disclosures from Redmile Group and FMR LLC. The platform uses AI to summarize these documents for easier investor analysis.
Annexon (ANNX) EVP sells 5,566 shares to cover RSU tax withholding
Annexon, Inc.'s EVP and Chief Innovation Officer, Ted Yednock, sold 5,566 shares of common stock at a weighted average price of $5.42 per share on March 2, 2026. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs), not as a discretionary sale. Following this transaction, Yednock retains 154,161 directly owned shares of Annexon.
Annexon (ANNX) CFO Lew sells shares to cover RSU tax withholding
Annexon, Inc.'s EVP and CFO, Jennifer Lew, sold 5,565 shares of common stock at a weighted average price of $5.42 per share on March 2, 2026. This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). Following the sale, Lew directly holds 170,700 shares of Annexon common stock.
Annexon (ANNX) EVP Overdorf sells shares to cover RSU tax
Annexon, Inc.'s EVP & Chief Business Officer, Michael Overdorf, sold 4,339 shares of common stock at a weighted average price of $5.42 per share. This transaction was conducted to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs). After the sale, Overdorf directly owns 182,625 shares of Annexon common stock.
Annexon, Inc. (ANNX) CMO sells shares to cover tax obligations
Annexon, Inc.'s Chief Medical Officer, Jamie Dananberg, sold 5,820 shares of common stock at a weighted average price of $5.43 per share. This sale was conducted to cover tax withholding obligations associated with the vesting of restricted stock units. Following this transaction, Dananberg retains direct ownership of 123,582 Annexon common shares.
Director files sale notice for 5,566 ANNX shares (NASDAQ: ANNX)
A director of Annexon, Inc. (NASDAQ: ANNX) has filed a Form 144 notice for the proposed sale of 5,566 common shares. This sale is associated with restricted stock vesting on February 27, 2026. The filing also indicates a prior sale of 7,857 shares on February 18, 2026, and reports 119,632,804 common shares outstanding as of March 2, 2026.
ANNX (NASDAQ: ANNX) Rule 144 notice shows 5,894 shares to be sold; prior 5,290 sold
Annexon, Inc. (ANNX) has filed a Rule 144 notice indicating that 5,894 common shares are to be sold, stemming from restricted stock vesting for compensation. The filing also reports that 5,290 common shares were sold in the past three months by Dean R. Artis. Fidelity Brokerage Services LLC is named as the broker for the upcoming sale, with the market value of the shares to be sold noted as $31,979.67.
ANNX (NASDAQ) Rule 144: Insider sale of 6,225 shares; 4,339 vested
Annexon, Inc. (ANNX) filed a Rule 144 notice disclosing a proposed sale of Common stock. The filing indicates that 4,339 Common shares are tied to restricted stock vesting on February 27, 2026, and that Michael Overdorf sold 6,225 Common shares on February 18, 2026, for $31,764.30. The company's securities are traded on NASDAQ.
ANNX (NASDAQ: ANNX) Form 144 lists 5,565-share notice and recent insider sale
ANNX (NASDAQ: ANNX) has filed a Form 144 notice for the proposed sale of 5,565 common shares through Fidelity Brokerage Services LLC, with a record date of March 2, 2026. The filing also details a restricted stock vesting event on February 27, 2026, for 5,565 shares as "Compensation," and a previous insider sale by Jennifer Lew of 7,851 common shares on February 18, 2026. The filing's impact and sentiment are noted as "Neutral."
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of "Moderate Buy" by Brokerages
Annexon, Inc. (NASDAQ:ANNX) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 1-year price target of $17.00. Despite recent insider selling, institutional investors have shown increased interest, and the company is advancing its lead asset, ANX005, through Phase 2 clinical trials for neuroimmune and neurodegenerative diseases. Analyst ratings range from "sell" to "overweight," indicating mixed but generally positive sentiment.
ANNX Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of Annexon, Inc. (ANNX), including its income statement, balance sheet, cash flow statement, and key financial ratios. It highlights the company's financial health, noting its unprofitability with a net income of -$138.2M in fiscal year 2024 and a low Piotroski F-Score, indicating weak financial strength and accrual-driven earnings. The analysis projects an estimated cash runway of approximately 5 months based on its current burn rate.
Annexon Showcases Promising Drug Ahead of Pivotal Trial Data
Annexon Inc. (ANNX) saw its stock rise by 7.06% following positive investor sentiment ahead of a key event showcasing its drug vonaprument for geographic atrophy in dry AMD. While the company faces significant operational losses and profitability concerns, it maintains a strong balance sheet and positive technical momentum. The pivotal Phase 3 ARCHER II trial data for vonaprument is expected in late 2026, with regulatory designations like FDA Fast Track and EMA PRIME bolstering confidence in its potential success.
Annexon Showcases Emerging Treatment with Topline Data on Horizon
Annexon Inc. (ANNX) stock surged by 7.06% following positive clinical trial announcements and FDA designation for its vonaprument treatment for geographic atrophy in dry AMD, despite currently facing significant financial challenges with negative returns and a substantial pre-tax profit margin loss. The company's strong liquidity from a high current ratio and recent capital injections for research and development suggest a potential for turnaround if upcoming Phase 3 trials prove successful. Technical analysis indicates an upward trend and bullish investor interest, with key support and resistance levels to watch.
Annexon Inc expected to post a loss of 32 cents a share - Earnings Preview
Annexon Inc (ANNX) is projected to report a loss of 32 cents per share, according to a Refinitiv earnings preview. This information is provided by Reuters and pertains to an upcoming earnings announcement from the company.
